Regeneron Dupixent OKd. as the First Biologic for Young Children with Urticaria

 Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program

CSU is a chronic skin disease that causes itch and hives that can be debilitating for young children, especially for those whose disease remains uncontrolled

CSU marks the fifth disease driven in part by type 2 inflammation for which Dupixent is approved in children younger than 12 years of age

https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-us-first-biologic-medicine-young